Medication Cessation Risk Assessment — What Happens If All Medications Stop
Medication Cessation Risk Assessment
Query: What would happen if Ishamma stopped all medications tomorrow?
Current Active Medications
| Medication | Role | Wiki Page |
|---|---|---|
| Azacitidine (IV, 5d/cycle) | Hypomethylating agent — AML treatment | Azacitidine |
| Venetoclax (oral, 5d/cycle) | BCL-2 inhibitor — AML treatment | Venetoclax |
| Posaconazole (oral, daily) | Antifungal prophylaxis + CYP3A4 inhibitor for VEN boosting | Posaconazole |
| Acyclovir (oral, daily) | Antiviral prophylaxis (HSV/VZV) | Acyclovir |
Risk Assessment by Medication
1. Azacitidine + Venetoclax — HIGHEST RISK
Consequence: AML relapse/progression — potentially fatal within weeks to months.
Ishamma has adverse-risk Aml with 6 pathogenic mutations (RUNX1 4%, ASXL1 28%, BCOR 17%, SRSF2 31%, STAG2 16%, NRAS 3%). The Aza-Ven regimen is suppressing the leukemia — Day 21 BMBx (Bone Marrow Biopsy 2025 12 31) showed response (cellularity 60%→25-30%, reticulin improved), and CBC trends show recovery (Hb 6.8→10.5, WBC normalizing, ANC recovered).
Without continued treatment:
- Leukemic clones (particularly ASXL1 at 28% VAF and SRSF2 at 31% VAF) would re-expand
- Blood counts would deteriorate toward presenting values (Hb 6.8, WBC 2500, Plt 45K)
- Bone marrow failure would return: severe anemia, bleeding risk, infection susceptibility
- With adverse-risk molecular profile, relapse is typically rapid and chemoresistant
- No G-CSF support available (pegfilgrastim discontinued due to bone pain — Pegfilgrastim)
2. Posaconazole — DUAL RISK
Consequence: (a) Invasive fungal infection risk, (b) Loss of venetoclax pharmacokinetic boosting.
- ANC has dropped as low as 610 (Anc). Prolonged neutropenia without antifungal prophylaxis → high risk of invasive aspergillosis or candidiasis
- Posaconazole is the CYP3A4 inhibitor enabling venetoclax dose reduction (400mg → 50-100mg). Without it, the current venetoclax dose becomes subtherapeutic (~12-20% of needed exposure)
- Loss of posaconazole would simultaneously compromise both infection prevention and cancer treatment efficacy
3. Acyclovir — MODERATE-HIGH RISK
Consequence: Herpes zoster reactivation, potentially disseminated.
- Documented prior shingles history (Herpes Zoster)
- Zostavax ~2016 — efficacy likely waned after ~10 years
- Venetoclax-based immunosuppression increases VZV reactivation risk
- In an immunocompromised 81-year-old, disseminated zoster can cause post-herpetic neuralgia, visceral dissemination, or encephalitis
4. Undocumented Medications — UNKNOWN RISK
Non-oncology medications are not documented in the wiki. At 81 with Diabetes Mellitus (HbA1c 6.7%, improved to 5.7%), Ishamma may be on medications not captured: antihypertensives, diabetic medications, supplements, etc.
Timeline of Deterioration
| Timeframe | Expected Consequence |
|---|---|
| Days 1-7 | Fungal/viral infection vulnerability begins immediately; no acute change in blood counts expected (chemo effects persist briefly) |
| Weeks 2-4 | VZV reactivation risk rises; venetoclax effect wanes; early leukemic re-expansion possible |
| Weeks 4-8 | CBC decline as leukemic clones re-expand; fatigue, worsening anemia, infection episodes |
| Months 2-3 | Full relapse likely — severe pancytopenia, transfusion dependence, life-threatening infections/bleeding |
| Months 3-6 | Without treatment, adverse-risk AML in an 81-year-old carries very poor survival |
Compounding Factors
- No G-CSF backup: Pegfilgrastim was discontinued (bone pain, 2026-03-30). Without chemo AND without G-CSF, neutrophil production relies entirely on residual normal marrow vs. expanding leukemic clone.
- Age 81: Reduced marrow reserve, diminished immune reconstitution capacity, higher infection mortality.
- Adverse-risk molecular profile: RUNX1 + ASXL1 + SRSF2 mutations are associated with inferior overall survival, higher relapse rates, and resistance to salvage therapy. If the disease relapses after stopping treatment, restarting Aza-Ven may be less effective.
- Hyponatremia (Hyponatremia): Mild but persistent (Na 129-135). Would lose any treatment-related contribution, but also any protective monitoring.
Key Insight
The medications are not independent — they form an interlocking system:
- Aza-Ven controls the leukemia
- Posaconazole enables venetoclax dosing AND prevents fungal infection
- Acyclovir prevents viral reactivation during immunosuppression caused by Aza-Ven
- Removing any one component weakens the others
This assessment describes what the medical records indicate about each medication's role. It is not medical advice. Any medication changes must be discussed with Bijay Prabhakaran Nair and the treating oncology team at KIMS Health.
Gaps Identified
- Complete medication list unknown — non-oncology medications not documented. Prescription records needed in
raw/prescriptions/. - No drug levels documented — venetoclax/posaconazole trough levels would inform how quickly drug effect wanes after cessation.
- No MRD data — molecular response depth unknown; deeper response might mean slightly longer time to relapse, but adverse-risk biology argues against optimism.